Comparative analysis of epitope recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different autoimmune disorders

Clinical and Experimental Immunology

Volumn 118, Issue 3, 1999, Pages 349-356

  Powers, Alvin C ^a,b   Bavik, K ^a   Tremble, J ^c   Daw, K ^a   Scherbaum, W A ^d   Banga, J P ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Diabetes; Epitope; Glutamic acid decarboxylase; Monoclonal antibody

Indexed keywords

AMINO ACID; AUTOANTIBODY; EPITOPE; GLUTAMATE DECARBOXYLASE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY;

AMINO ACID ANALYSIS; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; DIABETOGENESIS; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE ENDOCRINE ADENOMATOSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; EPITOPES; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOGLOBULIN G; ISOENZYMES; MOLECULAR SEQUENCE DATA; POLYENDOCRINOPATHIES, AUTOIMMUNE; PRECIPITIN TESTS; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0032716704     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01030.x     Document Type: Article

References (49)

1. 1 Baekkeskov S, Aanstoot HJ, Christgau S et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347:151-6.
2. 2 Hagopian WA, Karlsen AE, Gottsater A et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest 1993; 91:368-74.
3. 3 Atkinson MA, Kaufman DL, Newman D, Tobin AJ, Maclaren NK. Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest 1993; 91:350-6.
4. 4 Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992; 89:283-92.
5. 5 Christie MR, Tun RY, Lo SS et al. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes 1992; 41:782-7.
6. 6 Rowley MJ, Mackay IR, Chen QY, Knowles WJ, Zimmet PZ. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 1992; 41:548-51.
7. 7 Seissler J, Amann J, Mauch L et al. Prevalence of autoantibodies to the 65-and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1993; 92:1394-9.
8. 8 Velloso LA, Kampe O, Hallberg A, Christmanson L, Betsholtz C, Karlsson FA. Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type I diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J Clin Invest 1993; 91:2084-90.
9. 9 Bjork E, Velloso LA, Kampe O, Karlsson FA. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes. Diabetes 1994; 43:161-5.
10. 10 Tuomi T, Bjorses P, Falorni A et al. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 1996; 81:1488-94.
11. 11 Solimena M, De Camilli P. Autoimmunity to glutamic acid decarboxylase (GAD) in stiff-man syndrome and insulin-dependent diabetes mellitus. Neurochem Res 1991; 14:452-7.
12. 12 Butler MH, Solimena M, Dirkx R, Hayday A, De Camilli P. Identification of a dominant epitope of glutamic acid decarboxylase (GAD-65) recognized by autoantibodies in stiff-man syndrome. J Exp Med 1993; 178:2097-106.
13. 13 Li L, Hagopian WA, Brashear R, Daniels T, Lemmark A. Identification of autoantibody epitopes of glutamic acid decarboxylase in stiff-man syndrome patients. J Immunol 1993; 152:930-4.
14. 14 Kim J, Manchuk M, Bugawan T et al. Higher titer autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen, GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994; 180:595-606.
15. 15 Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996; 156:818-25.
16. 16 Grimaldi LM, Martino G, Braghi S et al. Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol 1993; 34:57-64.
17. 17 Seissler J, Bieg S, Yassin N et al. Association between antibodies to the MR 67,000 isoform of glutamate decarboxylase (GAD) and type 1 (insulin-dependent) diabetes mellitus with coexisting autoimmune polyendocrine syndrome type II. Autoimmunity 1994; 19:231-8.
18. 18 Riley WJ. Autoimmune polyglandular syndromes. Hormone Res 1992; 38(Suppl. 2):9-15.
19. 19 Dinkel K, Meinck HM, Jury KM, Karges W, Richter W. Inhibition of gamma-aminobutyric acid synthesis by glutamic acid autoantibodies in stiff-man syndrome. Ann Neurol 1998; 44:194-201.
20. 20 Daw K, Powers AC. Two distinct glutamic acid decarboxylase autoantibody specificities in IDDM target different epitopes. Diabetes 1995; 44:216-20.
21. 21 Davenport C, Radford PM, Al-Bukhari TA, Lai M, Bottazzo GF, Todd I. Heterogeneity in the occurrence of a subset of autoantibodies to glutamic acid decarboxylase in autoimmune polyendocrine patients with islet cell antibodies. Clin Exp Immunol 1998; 111:497-505.
22. 22 Richter W, Shi Y, Baekkeskov S. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase. Proc Natl Acad Sci USA 1993; 90:2832-6.
23. 23 Richter W, Endl J, Eiermann TH et al. Human monoclonal islet cell antibodies from a patient with insulin-dependent diabetes mellitus reveal glutamate decarboxylase as the target antigen. Proc Natl Acad Sci USA 1992; 89:8467-71.
24. 24 Tremble J, Morgenthaler NG, Vlug A et al. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a non-diabetic patient with multiple autoantibodies and Graves disease: a comparison with those present in type I diabetes. J Clin Endocrinol Metab 1997; 82:2664-70.
25. 25 Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, Harrison LC, Participating Laboratories. High level of concordance between assays for glutamic acid decarboxylase antibodies: the first international glutamic acid decarboxylase antibody workshop. Diabetes 1994; 43:1005-9.
26. 26 Verge CF, Stenger D, Bonifacio E et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type I diabetes: combinatorial islet autoantibody workshop. Diabetes 1998; 47:1857-66.
27. 27 Hagopian WA, Michelsen B, Karlsen AE et al. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes 1993; 42:631-6.
28. 28 Ujihara N, Daw K, Gianani R, Boel E, Yu L, Powers AC. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes. Diabetes 1994; 43:968-75.
29. 29 Falorni A, Ackefors M, Carlberg C et al. Diagnostic sensitivity of immunodominant epitopes of glutamic acid decarboxylase (GAD65) autoantibodies in childhood IDDM. Diabetologia 1996; 39:1091-8.
30. 30 Schwartz HL, Chandonia JM, Kash SF et al. High-resolution autoreactive epitope mapping and structural modeling of the 65 kDa form of human glutamic acid decarboxylase. J Mol Biol 1999; 287:983-99.
31. 31 Richter W, Seissler J, Northemann W, Wolfahrt S, Meinck HM, Scherbaum WA. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome. Diabetes 1993; 42:1642-8.
32. 32 Syren K, Lindsay L, Stoehrer B et al. Immune reactivity of diabetes-associated human monoclonal autoantibodies defines multiple epitopes and detects two domain boundaries in glutamate decarboxylase. J Immunol 1996; 157:5208-14.
33. 33 Richter W, Eiermann TH, Endl J et al. Human monoclonal islet specific autoantibodies share features of islel cell and 64 kDa antibodies. Diabetologia 1993; 36:785-90.
34. 34 Richter W, Northemann W, Muller M, Bohm BO. Mapping of an autoreactive epitope within glutamate decarboxylase using a diabetes-associated human monoclonal autoantibody and an epitope cDNA library. Hybridoma 1996; 15:103-8.
35. 35 Ellis TM, Atkinson MA. The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nature Med 1996; 2:148-53.
36. 36 Maclaren NK, Alkinson MA. Insulin-dependent diabetes mellitus: the hypothesis of molecular mimicry between islet cell antigens and microorganisms. Mol Med Today 1997; 3:76-83.
37. 37 Schloot NC, Roep BO, Wegmann DR, Yu L, Wang TB, Eisenbarth GS. T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects. Diabetologia 1997; 40:332-8.
38. 38 Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994; 94:2125-9.
39. 39 Endl J, Otto H, Jung G et al. Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 1997; 99:2405-15.
40. 40 Wicker LS, Chen SL, Nepom GT et al. Naturally processed T cell epitopes from human glutamic acid decarhoxylase identified using mice transgenic for the type I diabetes-associated human MHC class II allele, DRBI*0401. J Clin Invest 1996; 98:2597-603.
41. 41 Patel SD, Cope AP, Congia M et al. Identification of immunodominant T cell epilopes of human glutamic acid decarboxylase 65 by using HLA-DR (alpha1 *0101,beta1 *0401) transgenic mice. Proc Natl Acid Sci USA 1997; 94:8082-7.
42. 42 Chao CC, McDevitt HO. Identification of immunogenic epitopes of GAD 65 presented by Ag7 in non-obese diabetic mice. Immunogenetics 1997; 46:29-34.
43. 43 Lohmann T, Leslie RD, Londei M. T cell clones to epitopes of glutamate acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. J Autoimmun 1996; 9:385-9.
44. 44 Quinn A, Sercarz EE. T cells with multiple fine specificities are used by non-obese diabetic (NOD) mice in the response to GAD (524-543) J Autoimmun 1996; 9:365-70.
45. 45 Kaufman DL, Clare-Salzler MJ, Tian J et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:69-72.
46. 46 Clare-Salzler MJ, Tobin AJ, Kaufman DL. Glutamale decarboxylase: an autoantigen in IDDM. Diabetes Care 1992; 15:132-5.
47. 47 Eisenbarth GS. Mouse or man. Is GAD the cause of type I diabetes? Diabetes Care 1994; 17:605-7.
48. 48 Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus, N Engl J Med 1994; 331:1428-36.
49. 49 Nagamine K, Peterson P, Scott HS et al. Positional cloning of the APECED gene. Nat Genet 1997; 17:393-8.